Shopping Cart 0
Cart Subtotal
AED 0

Zika Virus Infections-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 22020
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Zika Virus Infections-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Zika Virus Infections-Pipeline Review, H2 2017, provides an overview of the Zika Virus Infections (Infectious Disease) pipeline landscape.

Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Zika virus is a member of the Flaviviridae family. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Zika Virus Infections-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Zika Virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Zika Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Zika Virus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 9, 30, 25 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 9 and 5 molecules, respectively.

Zika Virus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Zika Virus Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Zika Virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Zika Virus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Zika Virus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Zika Virus Infections (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Zika Virus Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Zika Virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

Introduction

Zika Virus Infections-Overview

Zika Virus Infections-Therapeutics Development

Zika Virus Infections-Therapeutics Assessment

Zika Virus Infections-Companies Involved in Therapeutics Development

Zika Virus Infections-Drug Profiles

Zika Virus Infections-Dormant Project

Zika Virus Infections-Discontinued Products

Zika Virus Infections-Product Development Milestones

Appendix


List Of Figure

List of Figures

Number of Products under Development for Zika Virus Infections, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Zika Virus Infections, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Zika Virus Infections-Pipeline by Abivax SA, H2 2017

Zika Virus Infections-Pipeline by Acuitas Therapeutics Inc, H2 2017

Zika Virus Infections-Pipeline by Bharat Biotech International Ltd, H2 2017

Zika Virus Infections-Pipeline by BioCryst Pharmaceuticals Inc, H2 2017

Zika Virus Infections-Pipeline by Biotron Ltd, H2 2017

Zika Virus Infections-Pipeline by CaroGen Corp, H2 2017

Zika Virus Infections-Pipeline by Cocrystal Pharma Inc, H2 2017

Zika Virus Infections-Pipeline by Emergent BioSolutions Inc, H2 2017

Zika Virus Infections-Pipeline by Ennaid Therapeutics LLC, H2 2017

Zika Virus Infections-Pipeline by Etubics Corp, H2 2017

Zika Virus Infections-Pipeline by GeneOne Life Science Inc, H2 2017

Zika Virus Infections-Pipeline by GeoVax Labs Inc, H2 2017

Zika Virus Infections-Pipeline by Gilead Sciences Inc, H2 2017

Zika Virus Infections-Pipeline by GT Biopharma Inc, H2 2017

Zika Virus Infections-Pipeline by Hawaii Biotech Inc, H2 2017

Zika Virus Infections-Pipeline by Heat Biologics Inc, H2 2017

Zika Virus Infections-Pipeline by Hemispherx Biopharma Inc, H2 2017

Zika Virus Infections-Pipeline by Immunovaccine Inc, H2 2017

Zika Virus Infections-Pipeline by Johnson & Johnson, H2 2017

Zika Virus Infections-Pipeline by Kineta Inc, H2 2017

Zika Virus Infections-Pipeline by Moderna Therapeutics Inc, H2 2017

Zika Virus Infections-Pipeline by Mymetics Corp, H2 2017

Zika Virus Infections-Pipeline by NewLink Genetics Corp, H2 2017

Zika Virus Infections-Pipeline by Novalex Therapeutics Inc, H2 2017

Zika Virus Infections-Pipeline by Novavax Inc, H2 2017

Zika Virus Infections-Pipeline by PaxVax Inc, H2 2017

Zika Virus Infections-Pipeline by PlantForm Corp, H2 2017

Zika Virus Infections-Pipeline by Plex Pharmaceuticals Inc, H2 2017

Zika Virus Infections-Pipeline by Profectus BioSciences Inc, H2 2017

Zika Virus Infections-Pipeline by Prokarium Ltd, H2 2017

Zika Virus Infections-Pipeline by Replikins Ltd, H2 2017

Zika Virus Infections-Pipeline by Sanofi, H2 2017

Zika Virus Infections-Pipeline by Sirnaomics Inc, H2 2017

Zika Virus Infections-Pipeline by Spotlight Innovation Inc, H2 2017

Zika Virus Infections-Pipeline by Starpharma Holdings Ltd, H2 2017

Zika Virus Infections-Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017

Zika Virus Infections-Pipeline by Tamir Biotechnology Inc, H2 2017

Zika Virus Infections-Pipeline by TechnoVax Inc, H2 2017

Zika Virus Infections-Pipeline by Themis Bioscience GmbH, H2 2017

Zika Virus Infections-Pipeline by Theravectys SA, H2 2017

Zika Virus Infections-Pipeline by Valneva SE, H2 2017

Zika Virus Infections-Pipeline by Vaxart Inc, H2 2017

Zika Virus Infections-Pipeline by VBI Vaccines Inc, H2 2017

Zika Virus Infections-Pipeline by VLP Therapeutics LLC, H2 2017

Zika Virus Infections-Dormant Projects, H2 2017

Zika Virus Infections-Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Abivax SA

Acuitas Therapeutics Inc

Bharat Biotech International Ltd

BioCryst Pharmaceuticals Inc

Biotron Ltd

CaroGen Corp

Cocrystal Pharma Inc

Emergent BioSolutions Inc

Ennaid Therapeutics LLC

Etubics Corp

GeneOne Life Science Inc

GeoVax Labs Inc

Gilead Sciences Inc

GT Biopharma Inc

Hawaii Biotech Inc

Heat Biologics Inc

Hemispherx Biopharma Inc

Immunovaccine Inc

Johnson & Johnson

Kineta Inc

Moderna Therapeutics Inc

Mymetics Corp

NewLink Genetics Corp

Novalex Therapeutics Inc

Novavax Inc

PaxVax Inc

PlantForm Corp

Plex Pharmaceuticals Inc

Profectus BioSciences Inc

Prokarium Ltd

Replikins Ltd

Sanofi

Sirnaomics Inc

Spotlight Innovation Inc

Starpharma Holdings Ltd

Takeda Pharmaceutical Co Ltd

Tamir Biotechnology Inc

TechnoVax Inc

Themis Bioscience GmbH

Theravectys SA

Valneva SE

Vaxart Inc

VBI Vaccines Inc

VLP Therapeutics LLC

Zika Virus Infections-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Zika Virus Infections-Pipeline Review, H2 2017, provides an overview of the Zika Virus Infections (Infectious Disease) pipeline landscape.

Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Zika virus is a member of the Flaviviridae family. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Zika Virus Infections-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Zika Virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Zika Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Zika Virus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 9, 30, 25 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 9 and 5 molecules, respectively.

Zika Virus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Zika Virus Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Zika Virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Zika Virus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Zika Virus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Zika Virus Infections (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Zika Virus Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Zika Virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents

Introduction

Zika Virus Infections-Overview

Zika Virus Infections-Therapeutics Development

Zika Virus Infections-Therapeutics Assessment

Zika Virus Infections-Companies Involved in Therapeutics Development

Zika Virus Infections-Drug Profiles

Zika Virus Infections-Dormant Project

Zika Virus Infections-Discontinued Products

Zika Virus Infections-Product Development Milestones

Appendix


List Of Figure

List of Figures

Number of Products under Development for Zika Virus Infections, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Zika Virus Infections, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Zika Virus Infections-Pipeline by Abivax SA, H2 2017

Zika Virus Infections-Pipeline by Acuitas Therapeutics Inc, H2 2017

Zika Virus Infections-Pipeline by Bharat Biotech International Ltd, H2 2017

Zika Virus Infections-Pipeline by BioCryst Pharmaceuticals Inc, H2 2017

Zika Virus Infections-Pipeline by Biotron Ltd, H2 2017

Zika Virus Infections-Pipeline by CaroGen Corp, H2 2017

Zika Virus Infections-Pipeline by Cocrystal Pharma Inc, H2 2017

Zika Virus Infections-Pipeline by Emergent BioSolutions Inc, H2 2017

Zika Virus Infections-Pipeline by Ennaid Therapeutics LLC, H2 2017

Zika Virus Infections-Pipeline by Etubics Corp, H2 2017

Zika Virus Infections-Pipeline by GeneOne Life Science Inc, H2 2017

Zika Virus Infections-Pipeline by GeoVax Labs Inc, H2 2017

Zika Virus Infections-Pipeline by Gilead Sciences Inc, H2 2017

Zika Virus Infections-Pipeline by GT Biopharma Inc, H2 2017

Zika Virus Infections-Pipeline by Hawaii Biotech Inc, H2 2017

Zika Virus Infections-Pipeline by Heat Biologics Inc, H2 2017

Zika Virus Infections-Pipeline by Hemispherx Biopharma Inc, H2 2017

Zika Virus Infections-Pipeline by Immunovaccine Inc, H2 2017

Zika Virus Infections-Pipeline by Johnson & Johnson, H2 2017

Zika Virus Infections-Pipeline by Kineta Inc, H2 2017

Zika Virus Infections-Pipeline by Moderna Therapeutics Inc, H2 2017

Zika Virus Infections-Pipeline by Mymetics Corp, H2 2017

Zika Virus Infections-Pipeline by NewLink Genetics Corp, H2 2017

Zika Virus Infections-Pipeline by Novalex Therapeutics Inc, H2 2017

Zika Virus Infections-Pipeline by Novavax Inc, H2 2017

Zika Virus Infections-Pipeline by PaxVax Inc, H2 2017

Zika Virus Infections-Pipeline by PlantForm Corp, H2 2017

Zika Virus Infections-Pipeline by Plex Pharmaceuticals Inc, H2 2017

Zika Virus Infections-Pipeline by Profectus BioSciences Inc, H2 2017

Zika Virus Infections-Pipeline by Prokarium Ltd, H2 2017

Zika Virus Infections-Pipeline by Replikins Ltd, H2 2017

Zika Virus Infections-Pipeline by Sanofi, H2 2017

Zika Virus Infections-Pipeline by Sirnaomics Inc, H2 2017

Zika Virus Infections-Pipeline by Spotlight Innovation Inc, H2 2017

Zika Virus Infections-Pipeline by Starpharma Holdings Ltd, H2 2017

Zika Virus Infections-Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017

Zika Virus Infections-Pipeline by Tamir Biotechnology Inc, H2 2017

Zika Virus Infections-Pipeline by TechnoVax Inc, H2 2017

Zika Virus Infections-Pipeline by Themis Bioscience GmbH, H2 2017

Zika Virus Infections-Pipeline by Theravectys SA, H2 2017

Zika Virus Infections-Pipeline by Valneva SE, H2 2017

Zika Virus Infections-Pipeline by Vaxart Inc, H2 2017

Zika Virus Infections-Pipeline by VBI Vaccines Inc, H2 2017

Zika Virus Infections-Pipeline by VLP Therapeutics LLC, H2 2017

Zika Virus Infections-Dormant Projects, H2 2017

Zika Virus Infections-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

Abivax SA

Acuitas Therapeutics Inc

Bharat Biotech International Ltd

BioCryst Pharmaceuticals Inc

Biotron Ltd

CaroGen Corp

Cocrystal Pharma Inc

Emergent BioSolutions Inc

Ennaid Therapeutics LLC

Etubics Corp

GeneOne Life Science Inc

GeoVax Labs Inc

Gilead Sciences Inc

GT Biopharma Inc

Hawaii Biotech Inc

Heat Biologics Inc

Hemispherx Biopharma Inc

Immunovaccine Inc

Johnson & Johnson

Kineta Inc

Moderna Therapeutics Inc

Mymetics Corp

NewLink Genetics Corp

Novalex Therapeutics Inc

Novavax Inc

PaxVax Inc

PlantForm Corp

Plex Pharmaceuticals Inc

Profectus BioSciences Inc

Prokarium Ltd

Replikins Ltd

Sanofi

Sirnaomics Inc

Spotlight Innovation Inc

Starpharma Holdings Ltd

Takeda Pharmaceutical Co Ltd

Tamir Biotechnology Inc

TechnoVax Inc

Themis Bioscience GmbH

Theravectys SA

Valneva SE

Vaxart Inc

VBI Vaccines Inc

VLP Therapeutics LLC

chat_bubbleLet's Chat